glp-1 natural agonist What do GLP 1 receptor agonists actually do Dual-Target Insight into Drug Discovery
Description
52 In a phase 1b trial done to evaluate the safety, pharmacokinetics and pharmacodynamics of orforglipron in patients with T2DM, orforglipron resulted in significant reductions in HbA1c, fasting blood glucose and body weight, with an adverse event profile consistent with that of other GLP-1RA
What causes the weight loss to plateau, and what happens when you quit the drugs
The Phase III clinical SURMOUNT-1 (NCT04184622) for tirzepatide, is expected to be completed in the first half of 2024
Staying well-hydrated and following gradual titration schedules can improve tolerability
Enteroendocrine cells-sensory sentinels of the intestinal environment and orchestrators of mucosal immunity
adherence and sustainability determine long-term success
